Evidence map›Paper›PMID 36521097›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023

Adjuvant

Margaret A Tempero, Uwe Pelzer, Eileen M O'Reilly, Jordan Winter, Do-Youn Oh, Chung-Pin Li, Giampaolo Tortora, Heung-Moon Chang, Charles D Lopez, Tanios Bekaii-Saab and 22 more

Open access · bronzeAbstract readClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
90citing papers in PubMed, 2 pooled it
12.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

90 citing papers in PubMed, 2 syntheses or guidelines pooled it, 122 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article

30 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

32 authors at 20 institutions in 11 countries.

Margaret A TemperoUniversity of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.ORCID 0000-0002-2777-9208
Uwe PelzerCharité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.
Eileen M O'ReillyMemorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-8076-9199
Jordan WinterThomas Jefferson University Hospital, Philadelphia, PA.ORCID 0000-0002-5200-6557
Do-Youn OhSeoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea.ORCID 0000-0003-1663-9901
Chung-Pin LiDivision of Clinical Skills Training, Department of Medical Education, Taipei Veterans General Hospital, Taipei, Taiwan.ORCID 0000-0003-2123-8264
Giampaolo TortoraAzienda Ospedaliera Universitaria, Verona, Italy.ORCID 0000-0002-1378-4962
Heung-Moon ChangAsan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Charles D LopezOregon Health & Science University, Knight Cancer Institute, Portland, OR.
Tanios Bekaii-SaabMayo Clinic Cancer Center, Mayo Clinic, Phoenix, AZ.ORCID 0000-0001-7721-1699
Andrew H KoUniversity of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.
Armando SantoroDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.ORCID 0000-0003-1709-9492
Joon Oh ParkDivision of Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.ORCID 0000-0001-6502-2612
Marcus S NoelDivision of Hematology/Oncology, Georgetown Lombardi Cancer Center, Washington, DC.
Giovanni Luca FrassinetiDepartment of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Yan-Shen ShanDepartment of Surgery, Institute of Clinical Medicine, College of Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.
Andrew DeanDepartment of Medical Oncology, St John of God Subiaco Hospital, Subiaco, Western Australia, Australia.ORCID 0000-0001-6632-2799
Hanno RiessCharité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.
Eric Van CutsemUniversity Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, Belgium.ORCID 0000-0002-6372-1230
Jordan BerlinVanderbilt-Ingram Cancer Center, Nashville, TN.ORCID 0000-0001-7571-2385
Philip PhilipKarmanos Cancer Institute, Detroit, MI.
Malcolm MoorePrincess Margaret Hospital, Toronto, Ontario, Canada.
David GoldsteinNelune Cancer Center, Prince of Wales Hospital, University of New South Wales, Randwick, New South Wales, Australia.
Josep TaberneroVall d'Hebron Hospital Campus and Institute of Oncology (VHIO), IOB-Quiron, UVic-UCC, Barcelona, Spain.ORCID 0000-0002-2495-8139
Mingyu LiBristol Myers Squibb, Princeton, NJ.
Stefano FerraraCelgene Research SLU, a Bristol Myers Squibb Company, Boudry, Switzerland.
Yvan Le BruchecCelgene Research SLU, a Bristol Myers Squibb Company, Boudry, Switzerland.
George ZhangBristol Myers Squibb, Princeton, NJ.
Brian LuBristol Myers Squibb, Princeton, NJ.
Andrew V BiankinWolfson Wohl Cancer Research Center, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.ORCID 0000-0002-0362-5597
Michele ReniIRCCS Ospedale San Raffaele Vita e Salute University, Milan, Italy.
APACT Investigators
Bristol-Myers Squibb (United States) · USUniversity of California, San Francisco · USBristol-Myers Squibb (Switzerland) · CHGeorgetown University Medical Center · USGlasgow Royal Infirmary · GBHumboldt-Universität zu Berlin · DEOregon Health & Science University · USAgostino Gemelli University Polyclinic · ITHenry Ford Hospital · USHumanitas University · ITIRCCS Ospedale San Raffaele · ITIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori · ITKU Leuven · BEMayo Clinic Hospital · USMemorial Sloan Kettering Cancer Center · USNational Cheng Kung University Hospital · TWNational Yang Ming Chiao Tung University · TWPrincess Margaret Cancer Centre · CASamsung Medical Center · KRSeoul National University · KR

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

purposeThis randomized, open-label trial compared the efficacy and safety of adjuvant

methodsWe assigned 866 treatment-naive patients with pancreatic ductal adenocarcinoma to

resultsTwo hundred eighty-seven of 432 patients and 310 of 434 patients completed

conclusionThe primary end point (independently assessed DFS) was not met despite favorable OS seen with

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsAdjuvants, ImmunologicAlbuminsAntineoplastic Combined Chemotherapy ProtocolsDeoxycytidineGemcitabineHumansPaclitaxel130-nm albumin-bound paclitaxelAdjuvants, ImmunologicAlbuminsDeoxycytidineGemcitabinePaclitaxel

Identifiers

PMID36521097
PMCPMC10082313
OpenAlexW4311672560

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.